Related Experiment Videos
Treatment of mice with methamphetamine produces cell loss in the substantia nigra
P K Sonsalla1, N D Jochnowitz, G D Zeevalk
1Department of Neurology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway 08854, USA.
Abstract:
Studies were conducted to determine if treatment of mice with methamphetamine (METH) would produce a loss of dopaminergic cells in the substantia nigra. The number of TH+/Nissl-stained was significantly decreased in both Swiss-Webster (S-W) and C57bl mice (approx. cell loss of 40% and 45%, respectively) 5-8 days after treatment with METH. In these same mice there was a corresponding decrease in neostriatal dopamine (DA) content (90% and 92%, respectively). In parallel studies, treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produced similar neuropathological effects. The finding that nigral cell loss occurs after METH treatment indicates that the METH-treated mouse may be a very relevant model of Parkinson's disease (PD).
Insights
Methamphetamine (METH) treatment significantly reduced dopaminergic cells in mouse substantia nigra, mirroring Parkinson's disease pathology. This METH-induced mouse model offers valuable insights for Parkinson's disease research.
Area of Science:
- Neuroscience
- Pharmacology
- Neuropathology
Background:
- Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra.
- Understanding the mechanisms of dopaminergic cell death is crucial for developing effective PD treatments.
- Animal models are essential for studying neurodegenerative diseases like PD.
Purpose of the Study:
- To investigate whether methamphetamine (METH) exposure induces dopaminergic cell loss in the substantia nigra of mice.
- To evaluate the relevance of METH-treated mice as a model for Parkinson's disease.
Main Methods:
- Administration of methamphetamine (METH) to Swiss-Webster (S-W) and C57bl mice.
- Quantification of tyrosine hydroxylase-positive (TH+/Nissl-stained) dopaminergic cells in the substantia nigra.
- Measurement of dopamine (DA) content in the neostriatum.
- Parallel studies using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for comparison.
Main Results:
- METH treatment caused a significant decrease in TH+ cells in the substantia nigra (approx. 40-45% loss) 5-8 days post-treatment.
- A corresponding substantial reduction in neostriatal dopamine content (approx. 90-92%) was observed in METH-treated mice.
- MPTP treatment yielded similar neuropathological effects, validating the experimental approach.
Conclusions:
- Methamphetamine administration leads to significant dopaminergic neurodegeneration in the substantia nigra.
- The observed nigral cell loss and dopamine depletion in METH-treated mice closely resemble key pathological features of Parkinson's disease.
- The METH-treated mouse represents a highly relevant and valuable preclinical model for studying Parkinson's disease pathogenesis and therapeutic strategies.